Lupin gets FDA nod for prostate cancer drug

26 Jun 2026via The Economic TimesSource

English हिंदी తెలుగు தமிழ்ಕನ್ನಡ मराठी বাংলা ગુજરાતી

Lupin gets FDA nod for prostate cancer drug — Lupin has received tentative approval from the USFDA for its prostate cancer treatment drug. The approval allows Lupin to launch the drug upon patent expiry or settlement. This move strengthens its oncology portfolio in the key US market. 📊 STOCKS: LUPIN | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #pharma

#FDA#Lupin#pharma#tentative-approval

Stocks mentioned

LUPINLUPIN

⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.

Trade smarter on NSE

Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.

Start for ₹1 →